Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and DIH Holding US (NASDAQ:DHAI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.
Volatility & Risk
Lucid Diagnostics has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, DIH Holding US has a beta of -0.65, suggesting that its stock price is 165% less volatile than the S&P 500.
Insider & Institutional Ownership
74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 27.8% of DIH Holding US shares are owned by institutional investors. 8.8% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 49.6% of DIH Holding US shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucid Diagnostics | 0 | 0 | 4 | 1 | 3.20 |
| DIH Holding US | 0 | 0 | 0 | 0 | 0.00 |
Lucid Diagnostics presently has a consensus price target of $3.69, indicating a potential upside of 269.12%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than DIH Holding US.
Earnings and Valuation
This table compares Lucid Diagnostics and DIH Holding US”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lucid Diagnostics | $4.19 million | 14.15 | -$52.67 million | ($1.14) | -0.88 |
| DIH Holding US | $64.47 million | 0.67 | -$8.44 million | N/A | N/A |
DIH Holding US has higher revenue and earnings than Lucid Diagnostics.
Profitability
This table compares Lucid Diagnostics and DIH Holding US’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucid Diagnostics | -1,069.87% | N/A | -123.54% |
| DIH Holding US | N/A | -5.07% | 3.35% |
Summary
Lucid Diagnostics beats DIH Holding US on 8 of the 13 factors compared between the two stocks.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
About DIH Holding US
DIH Holding US, Inc. operates as a robotics and virtual reality (VR) technology provider for the rehabilitation industry in Europe, the Middle East, Africa, the United States, and the Asia Pacific. It offers ArmeoPower, a backbone robot for arm and hand therapy in an early stage of rehabilitation; ArmeoSpring for less severe patients that provides self-initiated repetitive arm and hand therapy in an extensive workspace; ArmeoSpring Pro; and Armeo Senso, for patients self-initiated and still structurally controlled movement patterns to completely open movement. The company also provides lower extremity products, including Erigo for gradual verticalization, leg mobilization, and intensive sensorimotor stimulation through cyclic leg loading; Lokomat, a robot-assisted therapy that enables training to increase the strength of muscles and a range of motion of joints in order to improve walking; Andago, a robotics smart control system that assists patients in walking naturally; C-Mill, creates a training environment; CAREN, a computer assisted rehabilitation environment; and GRAIL, an gait real-time analysis interactive lab solution for analysis training and research. In addition, it offers SafeGait, RYSEN, and M-Gait for gait and balance; and HocoNet and D-Flow software. DIH Holding US, Inc. was founded in 2021 and is based in Norwell, Massachusetts.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
